SenoGuard

Groundbreaking Cryoablation Results

Robb Finnemore

Published on Apr 3

Valued Investors,

 SenoGuard continues to make exciting progress toward its mission of ensuring that no woman is denied breast cancer treatment due to cost or lack of access.

 We’re pleased to share that we recently completed the first phase of research funded by our $1 million NSF grant. The results, generated by internationally renowned cell-molecular biologist and cryoengineer Dr. John Baust of CPSI Biotech, exceeded our expectations. Dr. Baust commented on the results: “Our R&D has shown that SenoGuard’s cryoablation probe, combined with the SCN cryoengine, produces a colder, more destructive freeze in a fraction of the time taken by conventional devices. The CPSI team looks forward to helping bring this groundbreaking technology to the clinic."

We are now preparing to launch the second phase of this pivotal research.

 In addition to our scientific milestones, SenoGuard has received growing recognition within the medical and scientific communities. Our CEO, Diana Tucker, presented a poster at the 2025 National Consortium of Breast Centers (NCBC) conference. We also submitted an abstract to present at CRYO2025 in Hannover, and are proud to report that our submission was accepted.

With the continued support of the NSF grant and the proceeds from our WeFunder crowdfunding campaign, we’re confident in our ability to build on this momentum.

Thank you for your belief in our mission and your support of our work. We look forward to a successful and impactful journey together.

 Warm regards,

The SenoGuard Team


You're the first one here!

Early people don't usually get a prize, so here's a love letter from us.